Contemporary murine models in preclinical astrocytoma drug development.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neuro-Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/neuonc/nou288PMID 25246428PMCID PMC4483055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Glioblastoma: from molecular pathology to targeted treatment.

  2014influential reference
• Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

  2014cited by this paper
• Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

  2014cited by this paper
• Pyroglutamylated Amyloid-beta correlates with Hyperphosphorylated Tau and Severity of Alzheimer's Disease

  2014cited by this paper
• Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

  2014cited by this paper
• Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

  2014cited by this paper
• New cast for a new era: preclinical cancer drug development revisited.

  2013cited by this paper
• Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.

  2013cited by this paper
• Evolutionary etiology of high-grade astrocytomas

  2013cited by this paper
• Cancer stem cells in glioma: challenges and opportunities.

  2013cited by this paper
• Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

  2013cited by this paper
• Akt and c-Myc Induce Stem-Cell Markers in Mature Primary p53−/− Astrocytes and Render These Cells Gliomagenic in the Brain of Immunocompetent Mice

  2013cited by this paper
• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

  2013cited by this paper
• CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

  2013cited by this paper
• Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach

  2013cited by this paper
• Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

  2013cited by this paper
• Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

  2013cited by this paper
• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.

  2013cited by this paper
• The evolving landscape of glioblastoma stem cells.

  2013cited by this paper
• Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.

  2013cited by this paper
• Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• The causes and consequences of genetic heterogeneity in cancer evolution

  2013cited by this paper
• Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition

  2013cited by this paper
• Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ.

  2013influential reference
• Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

  2013cited by this paper
• Medulloblastoma molecular dissection: the way toward targeted therapy

  2013cited by this paper
• A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1

  2013cited by this paper
• Personalizing oncology: perspectives and prospects.

  2013cited by this paper
• Glioblastoma: molecular analysis and clinical implications.

  2013cited by this paper
• Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

  2013cited by this paper
• The integrated landscape of driver genomic alterations in glioblastoma

  2013cited by this paper
• Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

  2013cited by this paper
• LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program

  2013cited by this paper
• High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models

  2013cited by this paper
• Patient-derived tumour xenografts as models for oncology drug development

  2012cited by this paper
• IDH mutation impairs histone demethylation and results in a block to cell differentiation

  2012cited by this paper
• Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system

  2012cited by this paper
• An in vivo patient-derived model of endogenous IDH1-mutant glioma.

  2012cited by this paper
• In vivo models of primary brain tumors: pitfalls and perspectives

  2012influential reference
• Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Glioblastoma Cancer Stem-Like Cells: Implications for Pathogenesis and Treatment

  2012cited by this paper
• Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

  2012cited by this paper
• Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

  2012cited by this paper
• Matching mice to malignancy: molecular subgroups and models of medulloblastoma

  2012influential reference
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  2012cited by this paper
• The clinical implications of medulloblastoma subgroups

  2012cited by this paper
• IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

  2012cited by this paper
• Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

  2012cited by this paper
• Mutant IDH1 is required for IDH1 mutated tumor cell growth

  2012cited by this paper
• Genetically engineered mouse models of diffuse gliomas.

  2012influential reference
• Emerging insights into the molecular and cellular basis of glioblastoma.

  2012cited by this paper
• D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.

  2012cited by this paper
• A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Malignant glioma: lessons from genomics, mouse models, and stem cells.

  2012cited by this paper
• Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

  2012cited by this paper
• Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

  2012cited by this paper
• Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

  2012cited by this paper
• Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

  2011cited by this paper
• Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

  2011cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

  2011cited by this paper
• Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.

  2011cited by this paper
• Genetic modeling of gliomas in mice: New tools to tackle old problems

  2011cited by this paper
• Mosaic analysis with double markers reveals tumor cell of origin in glioma.

  2011cited by this paper
• Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions

  2011cited by this paper
• Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

  2011cited by this paper
• Murine L1210 and P388 Leukemias

  2011cited by this paper
• Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

  2011cited by this paper
• Acquired MET Expression Confers Resistance to EGFR Inhibition In a Mouse Model of Glioblastoma Multiforme

  2011cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010influential reference
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Oligodendroglioma cell lines containing t(1;19)(q10;p10).

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain*

  2010cited by this paper
• Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

  2010cited by this paper
• The transcriptional network for mesenchymal transformation of brain tumours

  2010cited by this paper
• Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme

  2010cited by this paper
• PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

  2010cited by this paper
• Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.

  2010cited by this paper
• A multigene predictor of outcome in glioblastoma.

  2010influential reference
• Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

  2010influential reference
• Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting

  2010cited by this paper
• Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

  2010cited by this paper
• U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line

  2010cited by this paper
• Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma

  2009cited by this paper
• High-grade glioma mouse models and their applicability for preclinical testing.

  2009cited by this paper
• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  2009cited by this paper
• The transcriptional network for mesenchymal transformation of brain tumors

  2009cited by this paper

• Comparison of lipid alterations in astrocytomas with increasing grade

  2024cites this paper
• Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma

  2024cites this paper
• Advances in Intraoperative Molecular Pathology-Guided Diagnosis and Treatment of Gliomas

  2024cites this paper
• Modeling glioblastoma complexity with organoids for personalized treatments.

  2023cites this paper
• Preclinical Experimental Models for Human Glioma

  2023cites this paper
• Abrogation of Rb Tumor Suppression Initiates GBM in Differentiated Astrocytes by Driving a Progenitor Cell Program

  2022cites this paper
• Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

  2021cites this paper
• OTT_A_254292 10593..10605

  2020cites this paper
• End Processing Factor APLF Promotes NHEJ Efficiency and Contributes to TMZ- and Ionizing Radiation-Resistance in Glioblastoma Cells

  2020cites this paper
• Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

  2019cites this paper
• Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma

  2018cites this paper
• Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.

  2018cites this paper
• An Overview of Preclinical Mouse Models for Brain Tumors

  2018cites this paper
• Blood–Brain Barrier and Edema in Brain Tumors

  2017cites this paper
• Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies

  2017cites this paper
• Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

  2017cites this paper
• Intra-Cavity Stem Cells Target Post-Surgical Brain Tumor Progression In Novel Resection And Recurrence Mouse Models

  2017cites this paper
• Advances in Biology and Treatment of Glioblastoma

  2017cites this paper
• Scalp Metastasis from Glioblastoma Multiforme: A Case Report and Literature Review.

  2017cites this paper
• Development of induced glioblastoma by implantation of a human xenograft in Yucatan minipig as a large animal model.

  2017cites this paper
• Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma

  2017cites this paper
• Preclinical Immunotherapeutic Animal Models for Brain Tumors

  2017cites this paper
• Tumor-homing cytotoxic human induced neural stem cells for cancer therapy

  2017cites this paper
• Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

  2016cites this paper
• BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis.

  2016influential citation
• Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

  2016cites this paper
• Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.

  2016cites this paper
• Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.

  2016influential citation